stoxline Quote Chart Rank Option Currency Glossary
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
3.69  -0.1 (-2.64%)    04-12 16:00
Open: 3.72
High: 3.81
Volume: 91,274
Pre. Close: 3.79
Low: 3.66
Market Cap: 103(M)
Technical analysis
2024-04-12 4:51:58 PM
Short term     
Mid term     
Targets 6-month :  4.75 1-year :  5.55
Resists First :  4.07 Second :  4.75
Pivot price 3.57
Supports First :  3.2 Second :  2.67
MAs MA(5) :  3.68 MA(20) :  3.41
MA(100) :  3.97 MA(250) :  4.82
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  74.9 D(3) :  72.9
RSI RSI(14): 53.2
52-week High :  9.25 Low :  2.67
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RVPH ] has closed below upper band by 39.3%. Bollinger Bands are 31.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.81 - 3.83 3.83 - 3.84
Low: 3.61 - 3.64 3.64 - 3.66
Close: 3.65 - 3.69 3.69 - 3.72
Company Description

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

Headline News

Sun, 14 Apr 2024
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Update - MarketBeat

Thu, 28 Mar 2024
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual ... - GlobeNewswire

Thu, 28 Mar 2024
Premarket Mover: Reviva Pharmaceuticals Holdings, Inc. (RVPH) Up 9.23% - InvestorsObserver

Wed, 27 Mar 2024
Is it Time to Dump Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock After it Has Risen 33.93% in a Week? - InvestorsObserver

Tue, 26 Mar 2024
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual ... - GlobeNewswire

Sun, 17 Mar 2024
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Sees Significant Decrease in Short Interest - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 28 (M)
Shares Float 17 (M)
Held by Insiders 17.7 (%)
Held by Institutions 18.7 (%)
Shares Short 651 (K)
Shares Short P.Month 1,020 (K)
Stock Financials
EPS -1.68
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.38
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -158.4 %
Return on Equity (ttm) -636.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -24 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -2.2
PEG Ratio 0
Price to Book value -9.72
Price to Sales 0
Price to Cash Flow -4.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android